- Home
- MKTX vs LEGN Comparison
MKTX vs LEGN Comparison
Compare MKTX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKTX | LEGN |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MKTX | LEGN |
|---|---|---|
| Price | $178.62 | $22.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $212.50 | $69.67 |
| AVG Volume (30 Days) | 634.3K | ★ 2.6M |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.87 | N/A |
| Revenue | $839,263,000.00 | ★ $909,045,000.00 |
| Revenue This Year | $6.35 | $68.83 |
| Revenue Next Year | $8.31 | $51.27 |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | 3.37 | ★ 74.75 |
| 52 Week Low | $156.17 | $22.28 |
| 52 Week High | $239.99 | $45.30 |
Technical Indicators
Market Signals| Indicator | MKTX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.43 | 21.15 |
| Support Level | $163.33 | $26.43 |
| Resistance Level | $169.49 | $28.97 |
| Average True Range (ATR) | 3.65 | 1.36 |
| MACD | 1.98 | -0.45 |
| Stochastic Oscillator | 93.61 | 2.51 |
Price Performance
Historical ComparisonAbout MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.